markedly increases the clearance of tamoxifen
and reduces its serum
does not appear to affect aminoglutethimide
Theoretically, the combination of an oestrogen antagonist such as tamoxifen
and an aromatase inhibitor should provide additional benefit in the treatment of hormone-dependent cancers, however, no clinical
studies have yet found this to be so. This interaction may partly explain this. It may be preferable to use these drugs sequentially rather than concurrently.